Assertio Therapeutics (ASRT) Misses Q4 EPS by 99c

Assertio Therapeutics (NASDAQ: ASRT) reported Q4 EPS of ($1.06), $0.99 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $13.54 million versus the consensus estimate of $28.36 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• RBC Capital Starts Centene (CNC) at Sector Perform
• CopperTech Metals files for IPO on NYSE under ticker CUX